ARNPs United of Washington State

Proposed rule adding Lisdexamfetamine (Vyvanse) to the list of Schedule II nonnarcotic stimulants for the purpose of RCW 69.50.402(1)(c). Also adds binge eating disorder.

Posted over 3 years ago by Bob Smithing

This announcement has 2 attachments:
OTS-7390 (36 KB)
WSR 16-02-016 (40 KB)

Dear Interested Party,

The Washington Pharmacy Quality Assurance Commission invites you to participate in a public comment period and public rules hearing related to proposed rule making to amend WAC 246-887-040 --Designation of nonnarcotic stimulant drugs for the purposes of RCW 69.50.402(1)(c), and WAC 246-887-045 -- Prescribing, dispensing, or administering of Schedule II nonnarcotic stimulants. (WSR 16-02-016)

The proposed rule adds Lisdexamfetamine (also known by the brand name Vyvanse) to the list of Schedule II nonnarcotic stimulants for the purpose of RCW 69.50.402(1)(c). In addition, the proposed rule adds binge eating disorder (BED) in adults to the list of disease states or conditions for which Schedule II nonnarcotics can be prescribed, dispensed, or administered for those specific Schedule II nonnarcotic stimulants that have been approved by the federal Food and Drug Administration for such disease states or conditions. The amendment would allow practitioners to use Lisdexamfetamine to treat BED in adults.

Submit Comments:
Comments on this proposed rule are appreciated and will be accepted until February 29, 2016. You may submit comments by mail, email or fax to:

Doreen Beebe, Program Manager
Pharmacy Quality Assurance Commission
PO Box 47852, Olympia WA 98504-7852

Email :
Fax: (360) 236-2260

Public Rules Hearing
Date: March 3, 2016
Time: 9:30 a.m.
Location: Highline Community College
Mt. Constance Conference Room – Bldg 8, 2400 South 240th St, Des Moines WA 98198

We invite you to join the Commission's public listserv for updates on this and other rule activities at: